首页 > 最新文献

International Journal of Cancer Management最新文献

英文 中文
Brachial Plexopathy After Modified Radical Mastectomy: A Case Report 改良乳房根治术后臂丛病1例报告
IF 0.7 Q3 Medicine Pub Date : 2023-03-07 DOI: 10.5812/ijcm-134538
Hamidreza Azizifarsani, S. Khorasanizadeh, N. Arefian, F. Behnaz, Afsaneh Sadat Makeh, Arash Tafrishinejad
Introduction: Brachial plexus injury (BPI) is not a common complication of surgery and anesthesia, which may happen with varied mechanisms like over-abduction, no appropriate positioning, and upper limb stretching. The overall prognosis of BPIs is commonly satisfactory, but the poor function of the upper limb may not be fully recovered in all cases and may end in the permanent sequel in serious injuries. Case Presentation: This study reported a woman with breast cancer. She developed a right brachial plexopathy following a modified radical mastectomy. Upon conservative treatment, full recovery was achieved and normal function of the right upper limb was observed 3 months following the operation. Conclusions: The arm's extremely abnormal positioning during intraoperative manipulation and axillary retraction or hyper abduction can lead to BPI. Nerve injury can occur even in diabetic patients, whose blood glucose is well controlled and have no other risk factors. If the nerve structure is intact, spontaneous recovery can be expected with conservative management.
臂丛神经损伤(Brachial plexus injury, BPI)并不是手术和麻醉的常见并发症,其发生机制多种多样,如过度外展、体位不当、上肢拉伸等。bpi的总体预后通常是令人满意的,但在所有病例中,上肢功能不良可能无法完全恢复,严重损伤可能导致永久性后遗症。病例介绍:本研究报告了一例女性乳腺癌患者。她在改良乳房根治术后发展为右臂丛病。经保守治疗,患者完全恢复,术后3个月右上肢功能恢复正常。结论:术中操作时手臂位置异常及腋窝内收或超外展可导致BPI。即使血糖控制良好,无其他危险因素的糖尿病患者也可能发生神经损伤。如果神经结构完好,保守治疗可以预期自发恢复。
{"title":"Brachial Plexopathy After Modified Radical Mastectomy: A Case Report","authors":"Hamidreza Azizifarsani, S. Khorasanizadeh, N. Arefian, F. Behnaz, Afsaneh Sadat Makeh, Arash Tafrishinejad","doi":"10.5812/ijcm-134538","DOIUrl":"https://doi.org/10.5812/ijcm-134538","url":null,"abstract":"Introduction: Brachial plexus injury (BPI) is not a common complication of surgery and anesthesia, which may happen with varied mechanisms like over-abduction, no appropriate positioning, and upper limb stretching. The overall prognosis of BPIs is commonly satisfactory, but the poor function of the upper limb may not be fully recovered in all cases and may end in the permanent sequel in serious injuries. Case Presentation: This study reported a woman with breast cancer. She developed a right brachial plexopathy following a modified radical mastectomy. Upon conservative treatment, full recovery was achieved and normal function of the right upper limb was observed 3 months following the operation. Conclusions: The arm's extremely abnormal positioning during intraoperative manipulation and axillary retraction or hyper abduction can lead to BPI. Nerve injury can occur even in diabetic patients, whose blood glucose is well controlled and have no other risk factors. If the nerve structure is intact, spontaneous recovery can be expected with conservative management.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86362885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Silico and Experimental Analyses of Long Non-coding RNA TMPO-AS1 Expression in Iranian Patients with Gastric Cancer 伊朗胃癌患者长链非编码RNA TMPO-AS1表达的计算机和实验分析
IF 0.7 Q3 Medicine Pub Date : 2023-03-06 DOI: 10.5812/ijcm-130586
Elaheh Mohammadali, R. Safaralizadeh, Arash Poursheikhani, T. Asvadi, S. Teimourian, B. Baradaran
Background: In recent decades, many long non-coding RNAs (lncRNAs) have been reported to play a prominent role in tumorigenesis and the progression of human cancers, including gastric cancer (GC), a leading cause of cancer death in Iranian men and women. Studies have demonstrated that thymopoietin antisense transcript 1 (TMPO-AS1) was upregulated in different cancers by acting as an oncogenic lncRNA. Objectives: This study aimed to evaluate the expression of lncRNA TMPO-AS1 in Iranian patients with GC. Methods: In order to conduct the present study, 40 gastric tumor samples and 40 marginal noncancerous counterparts were collected. The characteristics of patients’ samples were recorded, and the TMPO-AS1 expression levels were evaluated by qRT-PCR analysis. The Cancer Genome Atlas (TCGA) data for TMPO-AS1 were used and analyzed through GEPIA and TANRIC online tools. Receiver operating characteristic (ROC) curve analysis was used to estimate the diagnostic value. Student t-test, one-way ANOVA, and chi-square test were accomplished via SPSS software. Results: Our data demonstrated that TMPO-AS1 was overexpressed in cancerous tissues compared to adjacent nonmalignant ones (P = 0.0076). None of the demographic and clinicopathological data were associated with TMPO-AS1 expression levels. The TCGA data demonstrated that TMPO-AS1 was upregulated in GC tissues in comparison to adjacent nonmalignant ones (P = 0.001). ROC curve analysis suggested that TMPO-AS1 expression levels could discriminate GC tumor tissues from normal ones (AUC = 0.699, P = 0.001). Conclusions: Altogether, in our study, we demonstrated that lncRNA TMPO-AS1 may be considered a biomarker in Iranian patients with GC. However, further investigations are required to confirm the potential application of this lncRNA in diagnosis, prognosis, and therapeutic applications of GC.
背景:近几十年来,许多长链非编码rna (lncRNAs)被报道在肿瘤发生和人类癌症的进展中发挥重要作用,包括胃癌(GC),这是伊朗男性和女性癌症死亡的主要原因。研究表明,胸腺生成素反义转录本1 (thymopoietin反义转录本1,TMPO-AS1)在不同的癌症中作为致癌lncRNA被上调。目的:本研究旨在评估伊朗胃癌患者中lncRNA TMPO-AS1的表达。方法:为开展本研究,收集了40例胃肿瘤标本和40例边缘非癌标本。记录患者样本特征,采用qRT-PCR分析TMPO-AS1表达水平。通过GEPIA和TANRIC在线工具对TMPO-AS1的癌症基因组图谱(TCGA)数据进行分析。采用受试者工作特征(ROC)曲线分析估计诊断价值。采用SPSS软件进行学生t检验、单因素方差分析和卡方检验。结果:我们的数据显示,与邻近的非恶性组织相比,TMPO-AS1在癌组织中过表达(P = 0.0076)。人口学和临床病理数据均与TMPO-AS1表达水平无关。TCGA数据显示,与癌旁非恶性组织相比,TMPO-AS1在胃癌组织中表达上调(P = 0.001)。ROC曲线分析表明,TMPO-AS1表达水平可以区分胃癌组织与正常组织(AUC = 0.699, P = 0.001)。结论:总之,在我们的研究中,我们证明了lncRNA TMPO-AS1可能被认为是伊朗GC患者的生物标志物。然而,该lncRNA在胃癌的诊断、预后和治疗应用方面的潜在应用还需要进一步的研究。
{"title":"In Silico and Experimental Analyses of Long Non-coding RNA TMPO-AS1 Expression in Iranian Patients with Gastric Cancer","authors":"Elaheh Mohammadali, R. Safaralizadeh, Arash Poursheikhani, T. Asvadi, S. Teimourian, B. Baradaran","doi":"10.5812/ijcm-130586","DOIUrl":"https://doi.org/10.5812/ijcm-130586","url":null,"abstract":"Background: In recent decades, many long non-coding RNAs (lncRNAs) have been reported to play a prominent role in tumorigenesis and the progression of human cancers, including gastric cancer (GC), a leading cause of cancer death in Iranian men and women. Studies have demonstrated that thymopoietin antisense transcript 1 (TMPO-AS1) was upregulated in different cancers by acting as an oncogenic lncRNA. Objectives: This study aimed to evaluate the expression of lncRNA TMPO-AS1 in Iranian patients with GC. Methods: In order to conduct the present study, 40 gastric tumor samples and 40 marginal noncancerous counterparts were collected. The characteristics of patients’ samples were recorded, and the TMPO-AS1 expression levels were evaluated by qRT-PCR analysis. The Cancer Genome Atlas (TCGA) data for TMPO-AS1 were used and analyzed through GEPIA and TANRIC online tools. Receiver operating characteristic (ROC) curve analysis was used to estimate the diagnostic value. Student t-test, one-way ANOVA, and chi-square test were accomplished via SPSS software. Results: Our data demonstrated that TMPO-AS1 was overexpressed in cancerous tissues compared to adjacent nonmalignant ones (P = 0.0076). None of the demographic and clinicopathological data were associated with TMPO-AS1 expression levels. The TCGA data demonstrated that TMPO-AS1 was upregulated in GC tissues in comparison to adjacent nonmalignant ones (P = 0.001). ROC curve analysis suggested that TMPO-AS1 expression levels could discriminate GC tumor tissues from normal ones (AUC = 0.699, P = 0.001). Conclusions: Altogether, in our study, we demonstrated that lncRNA TMPO-AS1 may be considered a biomarker in Iranian patients with GC. However, further investigations are required to confirm the potential application of this lncRNA in diagnosis, prognosis, and therapeutic applications of GC.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88623467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 Adverse Outcomes in Immunocompromised Patients 免疫功能低下患者的COVID-19不良后果
IF 0.7 Q3 Medicine Pub Date : 2023-03-05 DOI: 10.5812/ijcm-131077
S. Shabani, P. Cheraghi, Haniyeh Ghaffari-Nazari, A. Hajifathali
Background: Coronavirus disease 2019 (COVID-19) is a devastating viral pandemic infecting millions of people with a wide range of symptoms from fever to death. It has been suggested that immunocompromised patients are at a higher risk of severe disease, poor clinical outcomes, and mortality. However, these patients’ risk factors and COVID-19-related outcomes are not well characterized. Objectives: We evaluated the COVID-19-related outcomes among immunocompromised patients ranging from solid tumors, hematological malignancies, and HIV to autoimmune disease and transplant recipients who received immunosuppressive agents. We also aimed at finding risk factors related to mortality among immunocompromised patients with COVID-19. Methods: This cross-sectional study was conducted in Khansari Hospital, Iran between March and November 2021. We included immunocompromised patients with nasal swab positive SARS-CoV-2 polymerase chain reaction (PCR) results in the study. Patient outcomes, including hospitalization ward and the mortality rate, were assessed till three months after COVID-19 infection were evaluated in all patients. Moreover, the relation between risk factors and the rate of the mortality rate was analyzed in immunocompromised patients with COVID-19. Results: A total number of 74 immunocompromised patients with solid tumors, hematologic malignancies, autoimmune diseases, acquired immunodeficiencies, and solid-organ transplant recipients were included in the study. Results indicated that the male gender and ICU hospitalization significantly increase the mortality risk. Surprisingly, chemotherapy is associated with a lower risk of mortality. Conclusions: Identifying the risk factors can improve the decision-making on cancer patients’ management during the COVID-19 infection. A further large cohort of patients would be required to identify risk factors relating to poor clinical outcomes and mortality rates in immunocompromised patients with COVID-19.
背景:2019冠状病毒病(COVID-19)是一种破坏性的病毒性大流行,感染了数百万人,出现从发烧到死亡的各种症状。已有研究表明,免疫功能低下的患者发生严重疾病、临床结果差和死亡率的风险更高。然而,这些患者的危险因素和covid -19相关结局尚未得到很好的表征。目的:我们评估了免疫功能低下患者的covid -19相关结果,包括实体瘤、血液系统恶性肿瘤、HIV、自身免疫性疾病和接受免疫抑制剂的移植患者。我们还旨在寻找与COVID-19免疫功能低下患者死亡率相关的危险因素。方法:这项横断面研究于2021年3月至11月在伊朗Khansari医院进行。我们纳入了鼻拭子SARS-CoV-2聚合酶链反应(PCR)结果阳性的免疫功能低下患者。在对所有患者进行COVID-19感染评估后三个月,评估患者预后,包括住院病房和死亡率。分析免疫功能低下患者的危险因素与死亡率的关系。结果:74例实体肿瘤、血液系统恶性肿瘤、自身免疫性疾病、获得性免疫缺陷和实体器官移植受者的免疫功能低下患者被纳入研究。结果显示,男性和ICU住院情况显著增加死亡风险。令人惊讶的是,化疗与较低的死亡率有关。结论:明确新冠肺炎感染期间癌症患者的危险因素可以改善患者的管理决策。需要进一步开展大规模的患者队列研究,以确定与COVID-19免疫功能低下患者的不良临床结果和死亡率相关的风险因素。
{"title":"COVID-19 Adverse Outcomes in Immunocompromised Patients","authors":"S. Shabani, P. Cheraghi, Haniyeh Ghaffari-Nazari, A. Hajifathali","doi":"10.5812/ijcm-131077","DOIUrl":"https://doi.org/10.5812/ijcm-131077","url":null,"abstract":"Background: Coronavirus disease 2019 (COVID-19) is a devastating viral pandemic infecting millions of people with a wide range of symptoms from fever to death. It has been suggested that immunocompromised patients are at a higher risk of severe disease, poor clinical outcomes, and mortality. However, these patients’ risk factors and COVID-19-related outcomes are not well characterized. Objectives: We evaluated the COVID-19-related outcomes among immunocompromised patients ranging from solid tumors, hematological malignancies, and HIV to autoimmune disease and transplant recipients who received immunosuppressive agents. We also aimed at finding risk factors related to mortality among immunocompromised patients with COVID-19. Methods: This cross-sectional study was conducted in Khansari Hospital, Iran between March and November 2021. We included immunocompromised patients with nasal swab positive SARS-CoV-2 polymerase chain reaction (PCR) results in the study. Patient outcomes, including hospitalization ward and the mortality rate, were assessed till three months after COVID-19 infection were evaluated in all patients. Moreover, the relation between risk factors and the rate of the mortality rate was analyzed in immunocompromised patients with COVID-19. Results: A total number of 74 immunocompromised patients with solid tumors, hematologic malignancies, autoimmune diseases, acquired immunodeficiencies, and solid-organ transplant recipients were included in the study. Results indicated that the male gender and ICU hospitalization significantly increase the mortality risk. Surprisingly, chemotherapy is associated with a lower risk of mortality. Conclusions: Identifying the risk factors can improve the decision-making on cancer patients’ management during the COVID-19 infection. A further large cohort of patients would be required to identify risk factors relating to poor clinical outcomes and mortality rates in immunocompromised patients with COVID-19.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74323536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Facilitating and Inhibiting Factors in Deciding to Start Retreatment in Survivors of Breast Cancer Recurrence 乳腺癌复发幸存者开始再治疗的促进和抑制因素
IF 0.7 Q3 Medicine Pub Date : 2023-03-05 DOI: 10.5812/ijcm-132709
M. Matbouei, M. Samsami, Mohsen Soleimani
Background: Cancer recurrence is an important care challenge for breast cancer survivors. It is necessary to understand and identify the barriers and facilitators that affect the decision to start retreatment by those facing breast cancer recurrence compared to factors affecting their decision to start the initial treatment, which is different. Objectives: This study is part of a qualitative study with a grounded theory approach, which was conducted to explain the facilitating and inhibiting factors affecting the decision to start retreatment in survivors of breast cancer recurrence, using a qualitative content analysis method. Methods: This study was conducted based on the experiences of 16 patients with breast cancer recurrence and 2 oncologists to confirm the findings of the effective inhibiting and facilitating factors in patients’ decisions to start retreatment for breast cancer recurrence in one of the hospitals in Tehran, Iran. The samples were selected, using the purposeful sampling method trying to have maximum diversity. Data were collected through in-depth semi-structured telephone interviews from November 2020 to November 2021 and analyzed, using the conventional content analysis method following the Elo and Kyngas method, which includes 3 phases, including the preparation phase, the organizing phase, and the reporting phase. Credibility, transferability, dependability, confirmability, and authenticity were used for determining the trustworthiness of data. Results: Both groups of inhibiting and facilitating factors were divided into 5 categories, including individual factors, social factors, family factors, illness characteristics, and treatment-related factors. Also, each category included sub-categories in two groups of inhibiting and facilitating factors affecting the decision to start treatment again. Conclusions: Based on the results of the present study, it is necessary to increase the awareness of patients with breast cancer by the treatment staff about the possibility of recurrence and to know the factors influencing their decision-making process to start retreatment. Nurses should play the role of advisors, educators, and supporters of the patients in this field.
背景:癌症复发是乳腺癌幸存者面临的一个重要的护理挑战。有必要了解和确定影响乳腺癌复发患者决定开始重新治疗的障碍和促进因素与影响他们决定开始初始治疗的因素相比,这是不同的。目的:本研究是一项扎根理论的定性研究的一部分,采用定性内容分析的方法,解释乳腺癌复发幸存者开始再治疗决策的促进因素和抑制因素。方法:本研究通过对伊朗德黑兰某医院16例乳腺癌复发患者和2名肿瘤学家的经验进行研究,以证实有效的抑制和促进乳腺癌复发患者决定开始再治疗的因素。样本的选择,使用有目的的抽样方法,尽量有最大的多样性。从2020年11月至2021年11月,通过深度半结构化电话访谈收集数据,采用传统的内容分析方法,遵循Elo和Kyngas方法,分为准备阶段、组织阶段和报告阶段3个阶段。可信度、可转移性、可靠性、可确认性和真实性被用来确定数据的可信度。结果:两组抑制因素和促进因素均分为5类,包括个体因素、社会因素、家庭因素、疾病特征和治疗相关因素。此外,每个类别还包括两组影响再次开始治疗决定的抑制和促进因素的子类别。结论:根据本研究结果,有必要提高治疗人员对乳腺癌患者复发可能性的认识,并了解影响其开始再治疗决策过程的因素。护士应该在这一领域扮演患者的顾问、教育者和支持者的角色。
{"title":"Facilitating and Inhibiting Factors in Deciding to Start Retreatment in Survivors of Breast Cancer Recurrence","authors":"M. Matbouei, M. Samsami, Mohsen Soleimani","doi":"10.5812/ijcm-132709","DOIUrl":"https://doi.org/10.5812/ijcm-132709","url":null,"abstract":"Background: Cancer recurrence is an important care challenge for breast cancer survivors. It is necessary to understand and identify the barriers and facilitators that affect the decision to start retreatment by those facing breast cancer recurrence compared to factors affecting their decision to start the initial treatment, which is different. Objectives: This study is part of a qualitative study with a grounded theory approach, which was conducted to explain the facilitating and inhibiting factors affecting the decision to start retreatment in survivors of breast cancer recurrence, using a qualitative content analysis method. Methods: This study was conducted based on the experiences of 16 patients with breast cancer recurrence and 2 oncologists to confirm the findings of the effective inhibiting and facilitating factors in patients’ decisions to start retreatment for breast cancer recurrence in one of the hospitals in Tehran, Iran. The samples were selected, using the purposeful sampling method trying to have maximum diversity. Data were collected through in-depth semi-structured telephone interviews from November 2020 to November 2021 and analyzed, using the conventional content analysis method following the Elo and Kyngas method, which includes 3 phases, including the preparation phase, the organizing phase, and the reporting phase. Credibility, transferability, dependability, confirmability, and authenticity were used for determining the trustworthiness of data. Results: Both groups of inhibiting and facilitating factors were divided into 5 categories, including individual factors, social factors, family factors, illness characteristics, and treatment-related factors. Also, each category included sub-categories in two groups of inhibiting and facilitating factors affecting the decision to start treatment again. Conclusions: Based on the results of the present study, it is necessary to increase the awareness of patients with breast cancer by the treatment staff about the possibility of recurrence and to know the factors influencing their decision-making process to start retreatment. Nurses should play the role of advisors, educators, and supporters of the patients in this field.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80420855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of 3D-Conformal Planning Using Partially Wide Tangents and Direct Photon/electron Portals for Breast Radiotherapy with Internal Mammary Nodes Inclusion: A Dosimetric Analysis 使用部分宽切线和直接光子/电子入口的3d适形计划用于乳房放射治疗与乳腺内淋巴结包络的比较:剂量学分析
IF 0.7 Q3 Medicine Pub Date : 2023-02-19 DOI: 10.5812/ijcm-116940
F. Farhan, Sepideh Sehat Kashani, F. Amouzegar-Hashemi, P. Haddad, M. Babaei, E. Esmati, R. Ghalehtaki, Mansoureh Nabavi, F. Jafari
Background: Internal mammary lymph nodes (IMNs) are a potential site of metastasis for breast cancer. Targeting IMNs as part of a comprehensive regional nodal irradiation comes at the cost of higher unwanted doses to critical nearby organs at risk. Thus, the efficacy and safety of different radiotherapy techniques for the coverage of this area remain elusive. Objectives: We present a dosimetric comparison between partially wide tangents (PWT) and direct photon/electron (P/E) portals in terms of target volume coverage and normal tissue sparing. Methods: Patients with left-sided breast cancer, who were referred to our clinic for post-lumpectomy or post-mastectomy radiotherapy, underwent computed tomography (CT) simulation. The left breast and IMNs, heart, lung, right breast, and esophagus were contoured. Dosimetric comparisons were based on dose-volume histograms (DVHs) generated for all of the aforementioned organs. A subgroup analysis was also performed based on patients’ type of surgical treatment. Results: A total of 30 patients (10 with breast conserving surgery and 20 with modified radical mastectomy) were included. The P/E plan provided a higher coverage of the left breast (P-value of CTV V105%: < 0.001) and IMNs with a P-value of 0.087 regarding the mean dose received by IMNs, and also less volume of the heart (P-value of Heart V30Gy: 0.021), and lungs (P-value of Lung V20Gy: 0.003) were irradiated. However, these advantages came at the cost of a higher dose to the esophagus and right breast and more hotspots compared to the PWT technique. Conclusions: The P/E technique had advantages regarding target volume coverage and toxicity regardless of the type of surgery. Based on the results of this study, overall, the P/E portal is superior to the PWT for radiotherapy of breast cancer with internal mammary node inclusion. However, the appropriate treatment plan should be decided on a case-by-case basis.
背景:乳腺内淋巴结(IMNs)是乳腺癌的潜在转移部位。作为全面区域淋巴结照射的一部分,以内神经网络为目标的代价是对危险的关键附近器官产生更高的不必要剂量。因此,不同放疗技术对该区域覆盖的有效性和安全性仍然难以捉摸。目的:我们提出了部分宽切线(PWT)和直接光子/电子(P/E)入口在靶体积覆盖和正常组织保留方面的剂量学比较。方法:转介至我院行乳房肿瘤切除术或乳房切除术后放疗的左侧乳腺癌患者,行计算机断层扫描(CT)模拟。左乳、内腔、心、肺、右乳及食道轮廓。剂量学比较是基于上述所有器官产生的剂量-体积直方图(DVHs)。根据患者的手术治疗类型进行亚组分析。结果:共纳入30例患者,其中保乳手术10例,改良乳房根治术20例。P/E方案对左乳房(CTV V105%的P值< 0.001)和IMNs (IMNs接受的平均剂量P值为0.087)的覆盖范围较大,对心脏(heart V30Gy的P值:0.021)和肺(Lung V20Gy的P值:0.003)的照射体积较小。然而,与PWT技术相比,这些优势的代价是对食道和右乳的剂量更高,并且有更多的热点。结论:无论手术类型如何,P/E技术在靶体积覆盖和毒性方面都具有优势。综合本研究结果,总体而言,P/E门脉在乳腺癌合并乳腺内淋巴结包埋的放疗中优于PWT。然而,适当的治疗计划应根据具体情况决定。
{"title":"Comparison of 3D-Conformal Planning Using Partially Wide Tangents and Direct Photon/electron Portals for Breast Radiotherapy with Internal Mammary Nodes Inclusion: A Dosimetric Analysis","authors":"F. Farhan, Sepideh Sehat Kashani, F. Amouzegar-Hashemi, P. Haddad, M. Babaei, E. Esmati, R. Ghalehtaki, Mansoureh Nabavi, F. Jafari","doi":"10.5812/ijcm-116940","DOIUrl":"https://doi.org/10.5812/ijcm-116940","url":null,"abstract":"Background: Internal mammary lymph nodes (IMNs) are a potential site of metastasis for breast cancer. Targeting IMNs as part of a comprehensive regional nodal irradiation comes at the cost of higher unwanted doses to critical nearby organs at risk. Thus, the efficacy and safety of different radiotherapy techniques for the coverage of this area remain elusive. Objectives: We present a dosimetric comparison between partially wide tangents (PWT) and direct photon/electron (P/E) portals in terms of target volume coverage and normal tissue sparing. Methods: Patients with left-sided breast cancer, who were referred to our clinic for post-lumpectomy or post-mastectomy radiotherapy, underwent computed tomography (CT) simulation. The left breast and IMNs, heart, lung, right breast, and esophagus were contoured. Dosimetric comparisons were based on dose-volume histograms (DVHs) generated for all of the aforementioned organs. A subgroup analysis was also performed based on patients’ type of surgical treatment. Results: A total of 30 patients (10 with breast conserving surgery and 20 with modified radical mastectomy) were included. The P/E plan provided a higher coverage of the left breast (P-value of CTV V105%: < 0.001) and IMNs with a P-value of 0.087 regarding the mean dose received by IMNs, and also less volume of the heart (P-value of Heart V30Gy: 0.021), and lungs (P-value of Lung V20Gy: 0.003) were irradiated. However, these advantages came at the cost of a higher dose to the esophagus and right breast and more hotspots compared to the PWT technique. Conclusions: The P/E technique had advantages regarding target volume coverage and toxicity regardless of the type of surgery. Based on the results of this study, overall, the P/E portal is superior to the PWT for radiotherapy of breast cancer with internal mammary node inclusion. However, the appropriate treatment plan should be decided on a case-by-case basis.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87114304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prevalence of Human Papillomavirus Genotypes in Women with Genital Warts Using Polymerase Chain Reaction (PCR) 聚合酶链式反应(PCR)检测人乳头瘤病毒基因型在尖锐湿疣女性中的流行
IF 0.7 Q3 Medicine Pub Date : 2023-02-08 DOI: 10.5812/ijcm-111191
M. Ghobadi, Haniyeh Bashi Zadeh Fakhar, Babak Shaghaghi
Background: The genotypic distribution of human papillomavirus (HPV) needs to be determined with detail as it is an important issue when it comes to public health and preparing vaccines since the HPV type may be different in various areas. Objectives: This study aimed at reporting the frequency of HPV types among women in Sari in the north of Iran. Methods: From 2018 October to 2019 April, 50 sterile swabs of vaginal and cervical discharge of women with genital warts, which were performed by a gynecologist, were examined to determine the prevalence of HPV genotyping by using polymerase chain reaction (PCR). Results: From 50 vaginal swab samples of patients with genital warts, the frequency distribution of types of HPV in women with genital warts included 5 patients (10.0%) with 2 high-risk serotypes as simultaneous serotypes 4% (16, 18), 4% (18, 35), 2% (66, 67), 1 patient (2%) HPV 33, 1 patient (2%) HPV 34, 1 patient (2%) 1 patient (2%) HPV 35, 2 patients (4%) HPV 66, 1 patient (2%) HPV 67, and 1 patient (2%) HPV 68. Conclusions: Since HPV genotype varies in diverse areas, these results can be used for screening, management, and vaccination of the target population against the common types of virus in Sari.
背景:人乳头瘤病毒(HPV)的基因型分布需要详细确定,因为它是一个重要的问题,当涉及到公共卫生和准备疫苗,因为不同地区的HPV类型可能不同。目的:本研究旨在报告伊朗北部萨里妇女中HPV类型的频率。方法:2018年10月至2019年4月,对妇科医生对50例尖锐湿疣妇女阴道和宫颈分泌物进行无菌拭子检测,采用聚合酶链反应(PCR)检测HPV基因分型的流行情况。结果:50例尖锐湿疣患者阴道拭子样本中,尖锐湿疣女性HPV类型的频率分布包括5例(10.0%),2种高危血清型,同时血清型为4%(16,18)、4%(18,35)、2%(66,67)、1例(2%)HPV 33、1例(2%)HPV 34、1例(2%)HPV 35、2例(4%)HPV 66、1例(2%)HPV 67、1例(2%)HPV 68。结论:由于HPV基因型在不同地区存在差异,这些结果可用于筛查、管理和针对Sari常见病毒类型的目标人群接种疫苗。
{"title":"The Prevalence of Human Papillomavirus Genotypes in Women with Genital Warts Using Polymerase Chain Reaction (PCR)","authors":"M. Ghobadi, Haniyeh Bashi Zadeh Fakhar, Babak Shaghaghi","doi":"10.5812/ijcm-111191","DOIUrl":"https://doi.org/10.5812/ijcm-111191","url":null,"abstract":"Background: The genotypic distribution of human papillomavirus (HPV) needs to be determined with detail as it is an important issue when it comes to public health and preparing vaccines since the HPV type may be different in various areas. Objectives: This study aimed at reporting the frequency of HPV types among women in Sari in the north of Iran. Methods: From 2018 October to 2019 April, 50 sterile swabs of vaginal and cervical discharge of women with genital warts, which were performed by a gynecologist, were examined to determine the prevalence of HPV genotyping by using polymerase chain reaction (PCR). Results: From 50 vaginal swab samples of patients with genital warts, the frequency distribution of types of HPV in women with genital warts included 5 patients (10.0%) with 2 high-risk serotypes as simultaneous serotypes 4% (16, 18), 4% (18, 35), 2% (66, 67), 1 patient (2%) HPV 33, 1 patient (2%) HPV 34, 1 patient (2%) 1 patient (2%) HPV 35, 2 patients (4%) HPV 66, 1 patient (2%) HPV 67, and 1 patient (2%) HPV 68. Conclusions: Since HPV genotype varies in diverse areas, these results can be used for screening, management, and vaccination of the target population against the common types of virus in Sari.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72524199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depth Analysis of Open Transhiatal Esophagectomy Outcomes (Orringer Technique) in Patients with Esophageal Cancer from 1990 to 2015: A 25-year Experience Single-center Study 1990年至2015年食管癌患者经食管切开切除术(Orringer技术)结果的深度分析:一项25年的单中心研究
IF 0.7 Q3 Medicine Pub Date : 2023-02-06 DOI: 10.5812/ijcm-107922
J. Khoshnevis, M. Akbari, Mohammadreza Kalantar Motamed, A. Moradi, Mohammad Ebrahimi, Meysam Jirabadi, Terifeh Dashti, Afsaneh Sadat Makeh, M. Karami, F. Moradian
: Esophageal cancer is an invasive tumor with rapid growth and a poor prognosis. The annual incidence of esophageal cancer in the United States is 6 per 100 000 men and 1.6 per 100 000 women. This is different in the case of Iran, and the number of patients in the country is higher than in other countries. In this evaluation, the researchers present the experience with open Transhiatal Esophagectomy (Orringer) technique outcomes. This study aimed at evaluating the Orringer technique and its complications in patients with esophageal cancer for 25 years at the Cancer Research Center of Shahid Beheshti University of Medical Sciences. This is a descriptive study conducted from the beginning of 1988 to 2016. In this study, 114 patients with a mean age of 55 years and a gender classification of 60% male and 40% female were evaluated. The present study and other experiences showed that non-radical surgery such as the Orringer technique is acceptable and compassable compared to radical surgery in 3 fields.
食管癌是一种生长迅速、预后差的侵袭性肿瘤。在美国,食管癌的年发病率是每10万男性6例,每10万女性1.6例。伊朗的情况有所不同,该国的患者人数高于其他国家。在这项评估中,研究人员介绍了开放式经食管切除术(Orringer)技术的结果。本研究旨在评估沙希德·贝赫什蒂医科大学癌症研究中心25年来食管癌患者的Orringer技术及其并发症。这是一项从1988年初到2016年的描述性研究。在本研究中,114例患者的平均年龄为55岁,性别分类为男性60%,女性40%。本研究和其他经验表明,与根治性手术相比,非根治性手术如Orringer技术在三个方面是可接受和可调和的。
{"title":"Depth Analysis of Open Transhiatal Esophagectomy Outcomes (Orringer Technique) in Patients with Esophageal Cancer from 1990 to 2015: A 25-year Experience Single-center Study","authors":"J. Khoshnevis, M. Akbari, Mohammadreza Kalantar Motamed, A. Moradi, Mohammad Ebrahimi, Meysam Jirabadi, Terifeh Dashti, Afsaneh Sadat Makeh, M. Karami, F. Moradian","doi":"10.5812/ijcm-107922","DOIUrl":"https://doi.org/10.5812/ijcm-107922","url":null,"abstract":": Esophageal cancer is an invasive tumor with rapid growth and a poor prognosis. The annual incidence of esophageal cancer in the United States is 6 per 100 000 men and 1.6 per 100 000 women. This is different in the case of Iran, and the number of patients in the country is higher than in other countries. In this evaluation, the researchers present the experience with open Transhiatal Esophagectomy (Orringer) technique outcomes. This study aimed at evaluating the Orringer technique and its complications in patients with esophageal cancer for 25 years at the Cancer Research Center of Shahid Beheshti University of Medical Sciences. This is a descriptive study conducted from the beginning of 1988 to 2016. In this study, 114 patients with a mean age of 55 years and a gender classification of 60% male and 40% female were evaluated. The present study and other experiences showed that non-radical surgery such as the Orringer technique is acceptable and compassable compared to radical surgery in 3 fields.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90642090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parasagittal Fibroblastic Meningioma in Accompaniment with Scalp Basal Cell Carcinoma: Report of a Case 旁矢状纤维母细胞脑膜瘤伴头皮基底细胞癌1例
IF 0.7 Q3 Medicine Pub Date : 2023-01-09 DOI: 10.5812/ijcm-131751
Sara Zandpazandi, Mohammadreza Shahmohammadi, Mehdi Farokhi
Introduction: Accompaniment of meningioma with other tumors especially cerebral tumors is quite rare. In some institutes, cases of simultaneous meningioma and glioma are seen and reported previously. Case Presentation: We reported a meningioma with the accompaniment of scalp basal cell carcinoma (BCC) with no signs and symptoms of Gorlin syndrome and no history of radiation. Conclusions: Expression of some adjacent cancerous lesions might have a local cancerous induction effect.
简介:脑膜瘤合并其他肿瘤,尤其是脑肿瘤是相当罕见的。在一些研究机构中,脑膜瘤和胶质瘤同时发生的病例也有报道。病例介绍:我们报告一例脑膜瘤伴头皮基底细胞癌(BCC),无Gorlin综合征体征和症状,无放射史。结论:部分癌旁病变的表达可能具有局部癌变诱导作用。
{"title":"Parasagittal Fibroblastic Meningioma in Accompaniment with Scalp Basal Cell Carcinoma: Report of a Case","authors":"Sara Zandpazandi, Mohammadreza Shahmohammadi, Mehdi Farokhi","doi":"10.5812/ijcm-131751","DOIUrl":"https://doi.org/10.5812/ijcm-131751","url":null,"abstract":"Introduction: Accompaniment of meningioma with other tumors especially cerebral tumors is quite rare. In some institutes, cases of simultaneous meningioma and glioma are seen and reported previously. Case Presentation: We reported a meningioma with the accompaniment of scalp basal cell carcinoma (BCC) with no signs and symptoms of Gorlin syndrome and no history of radiation. Conclusions: Expression of some adjacent cancerous lesions might have a local cancerous induction effect.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77307365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological Study of Hepatopancreatobiliary Sarcoma in Iran, 2010 - 2014 2010 - 2014年伊朗肝胆管肉瘤流行病学研究
IF 0.7 Q3 Medicine Pub Date : 2023-01-06 DOI: 10.5812/ijcm-118444
A. Tayebi, Faranak Olamaeian, Arash Pour Mohammad, M. Gholizadeh Mesgarha, Leila Asef-Kabiri, F. Moradian, Behrad Seyedesfahani, M. Akbari
Background: Hepatopancreatobiliary (HPB) malignancies are a relatively rare but important type of cancer with usually poor prognosis. Prompt diagnosis and treatment are crucial to improving the patient’s outcome. For this issue, acknowledgment of epidemiological characteristics is helpful. Objectives: In this study, the epidemiological characteristics of cases with HPB sarcoma among Iranian patients were assessed. Methods: In this epidemiological study, 133 consecutive cases with HPB sarcoma in Iran from 2010 to 2014 were evaluated, including gallbladder, pancreas, hepatic, pancreatic body and head, and other biliary tumors. Results: Nine gallbladder sarcoma cases were reported between 2010 and 2014, accounting for 6.7% of all HPB sarcoma cases, and leiomyosarcoma was the most common. A total of 16 patients of pancreatic origin were reported during this period, with the highest rate of 6 cases in 2011; in this sarcoma category, malignant type spindle cell tumor was the most common type accounting for 12.5% of all cases. Ninety-five cases of liver sarcomas were reported generally. Non-specified and desmoplastic small round cell tumors were the most common types. Five cases of pancreatic head sarcomas were reported during 2010 - 2013. There was no predominant tumor type. Five cases of pancreatic head sarcoma were reported during 2010 - 2013. There was no dominant tumor type. About the other biliary tract sites, six patients were reported. Gastrointestinal stromal sarcoma was the most common type. Conclusions: Hepatopancreatobiliary sarcoma in the Iranian population generally has diverse types, and there are different patterns according to the age and sex distribution in patients according to the initial location of the tumor and also their pathological subtypes.
背景:肝胰胆(HPB)恶性肿瘤是一种相对罕见但重要的癌症类型,通常预后较差。及时诊断和治疗对改善患者的预后至关重要。对于这个问题,承认流行病学特征是有帮助的。目的:本研究评估伊朗HPB肉瘤病例的流行病学特征。方法:本流行病学研究对2010 - 2014年伊朗连续133例HPB肉瘤进行评估,包括胆囊、胰腺、肝脏、胰腺体及头部等胆道肿瘤。结果:2010 - 2014年共报告胆囊肉瘤9例,占全部HPB肉瘤病例的6.7%,其中以平滑肌肉瘤最为常见。此期间共报告胰腺源性患者16例,2011年发生率最高,为6例;在该肉瘤类别中,恶性梭形细胞肿瘤是最常见的类型,占所有病例的12.5%。报告肝肉瘤95例。非特异性和结缔组织增生的小圆细胞瘤是最常见的类型。2010 - 2013年报告5例胰头肉瘤。无显性肿瘤类型。本文报告2010 - 2013年胰头肉瘤5例。无显性肿瘤类型。其他胆道部位,6例患者报道。胃肠道间质肉瘤是最常见的类型。结论:伊朗人群肝胆管肉瘤的类型普遍多样,根据肿瘤的初始位置和病理亚型,患者的年龄和性别分布也有不同的模式。
{"title":"Epidemiological Study of Hepatopancreatobiliary Sarcoma in Iran, 2010 - 2014","authors":"A. Tayebi, Faranak Olamaeian, Arash Pour Mohammad, M. Gholizadeh Mesgarha, Leila Asef-Kabiri, F. Moradian, Behrad Seyedesfahani, M. Akbari","doi":"10.5812/ijcm-118444","DOIUrl":"https://doi.org/10.5812/ijcm-118444","url":null,"abstract":"Background: Hepatopancreatobiliary (HPB) malignancies are a relatively rare but important type of cancer with usually poor prognosis. Prompt diagnosis and treatment are crucial to improving the patient’s outcome. For this issue, acknowledgment of epidemiological characteristics is helpful. Objectives: In this study, the epidemiological characteristics of cases with HPB sarcoma among Iranian patients were assessed. Methods: In this epidemiological study, 133 consecutive cases with HPB sarcoma in Iran from 2010 to 2014 were evaluated, including gallbladder, pancreas, hepatic, pancreatic body and head, and other biliary tumors. Results: Nine gallbladder sarcoma cases were reported between 2010 and 2014, accounting for 6.7% of all HPB sarcoma cases, and leiomyosarcoma was the most common. A total of 16 patients of pancreatic origin were reported during this period, with the highest rate of 6 cases in 2011; in this sarcoma category, malignant type spindle cell tumor was the most common type accounting for 12.5% of all cases. Ninety-five cases of liver sarcomas were reported generally. Non-specified and desmoplastic small round cell tumors were the most common types. Five cases of pancreatic head sarcomas were reported during 2010 - 2013. There was no predominant tumor type. Five cases of pancreatic head sarcoma were reported during 2010 - 2013. There was no dominant tumor type. About the other biliary tract sites, six patients were reported. Gastrointestinal stromal sarcoma was the most common type. Conclusions: Hepatopancreatobiliary sarcoma in the Iranian population generally has diverse types, and there are different patterns according to the age and sex distribution in patients according to the initial location of the tumor and also their pathological subtypes.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2023-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89042543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of I-CAM1, V-CAM1, and E-selectin Serum Levels in Patients with Breast and Pelvic Cancer: A Case Control Study 乳腺癌和盆腔癌患者血清I-CAM1、V-CAM1和e -选择素水平的评估:一项病例对照研究
IF 0.7 Q3 Medicine Pub Date : 2022-12-19 DOI: 10.5812/ijcm-124107
Ali Aminizadeh, L. Jarahi, Mohammad Bagher Khorami, Saba Mohseni, A. Bahrami, S. Hosseini, Hamidreza Rahimi
Background: Breast and pelvic cancers are the most prevalent cancers among women globally. Several studies have reported on the effect of cell adhesion molecules on the growth, multiplication, invasion, and metastasis of tumor cells as well as inflammatory biomarkers, which are responsible for harmful inflammatory processes. Objectives: The purpose of the current study was to assess the serum levels of adhesion molecules intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin in patients with cancer before and after radiotherapy, compare these with the levels of healthy subjects, and consider the relationship of these levels with the tumor origin. Methods: The present case-control study investigated 14 patients with breast cancer and 14 patients with pelvic cancer who had been referred to Omid Teaching Hospital’s oncology clinic, Mashhad, Iran between 2015 and 2017. Evaluated by the ELISA method for ICAM-1, VCAM-1, and E-selectin were the serum samples of these 28 cancer patients before and after their course of radiotherapy treatment and the serum samples of the 28 healthy subjects who had no history of cancer, radiotherapy or the risk factor of coronary artery disease. Results: The ICAM-1, VCAM-1, and E-selectin serum levels of all patients with cancer before and after a course of radiotherapy were significantly higher than those of the control group (P value ≤ 0.5). There was no significant difference between the two cancer groups before and after radiotherapy (P value ≥ 0.05). Conclusions: The current study demonstrated that the serum levels of adhesion molecules in patients with cancer before and after radiotherapy increase significantly regardless of the initial location of the tumor.
背景:乳腺癌和盆腔癌是全球女性中最常见的癌症。一些研究报道了细胞粘附分子对肿瘤细胞的生长、增殖、侵袭和转移以及炎症生物标志物的影响,这些生物标志物负责有害的炎症过程。目的:本研究旨在评估肿瘤患者放疗前后血清黏附分子细胞间黏附分子-1 (ICAM-1)、血管细胞黏附分子-1 (VCAM-1)和e-选择素的水平,并与健康受试者进行比较,并探讨这些水平与肿瘤起源的关系。方法:本病例对照研究调查了2015年至2017年在伊朗马什哈德奥米德教学医院肿瘤门诊转诊的14例乳腺癌和14例盆腔癌患者。采用ELISA法检测28例肿瘤患者放疗前后血清中ICAM-1、VCAM-1和e -选择素的含量,同时检测28例无癌症史、放疗史和冠状动脉疾病危险因素的健康受试者血清中ICAM-1、VCAM-1和e -选择素的含量。结果:所有癌症患者放疗前后血清ICAM-1、VCAM-1、e -选择素水平均显著高于对照组(P值≤0.5)。两癌组放疗前后差异无统计学意义(P值≥0.05)。结论:目前的研究表明,无论肿瘤的初始位置如何,肿瘤患者放疗前后血清粘附分子水平均显著升高。
{"title":"Assessment of I-CAM1, V-CAM1, and E-selectin Serum Levels in Patients with Breast and Pelvic Cancer: A Case Control Study","authors":"Ali Aminizadeh, L. Jarahi, Mohammad Bagher Khorami, Saba Mohseni, A. Bahrami, S. Hosseini, Hamidreza Rahimi","doi":"10.5812/ijcm-124107","DOIUrl":"https://doi.org/10.5812/ijcm-124107","url":null,"abstract":"Background: Breast and pelvic cancers are the most prevalent cancers among women globally. Several studies have reported on the effect of cell adhesion molecules on the growth, multiplication, invasion, and metastasis of tumor cells as well as inflammatory biomarkers, which are responsible for harmful inflammatory processes. Objectives: The purpose of the current study was to assess the serum levels of adhesion molecules intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin in patients with cancer before and after radiotherapy, compare these with the levels of healthy subjects, and consider the relationship of these levels with the tumor origin. Methods: The present case-control study investigated 14 patients with breast cancer and 14 patients with pelvic cancer who had been referred to Omid Teaching Hospital’s oncology clinic, Mashhad, Iran between 2015 and 2017. Evaluated by the ELISA method for ICAM-1, VCAM-1, and E-selectin were the serum samples of these 28 cancer patients before and after their course of radiotherapy treatment and the serum samples of the 28 healthy subjects who had no history of cancer, radiotherapy or the risk factor of coronary artery disease. Results: The ICAM-1, VCAM-1, and E-selectin serum levels of all patients with cancer before and after a course of radiotherapy were significantly higher than those of the control group (P value ≤ 0.5). There was no significant difference between the two cancer groups before and after radiotherapy (P value ≥ 0.05). Conclusions: The current study demonstrated that the serum levels of adhesion molecules in patients with cancer before and after radiotherapy increase significantly regardless of the initial location of the tumor.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80985700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Cancer Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1